Myrexis, Inc. (Formerly Known as Myriad Pharmaceuticals, Inc.) to Present Oral Anti-Interferon Program at American College of Rheumatology/Association of Rheumatology Health Professionals

SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.